P1.083. Sequential Versus Concurrent Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized, Controlled, Open-Label, Phase II Trial

Clicks: 2
ID: 325746
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #305 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Neoadjuvant chemotherapy combined with PD-1 inhibitors has application potential for locally advanced esophageal squamous cell carcinoma (ESCC), but there is no prospective evidence for the optimal timing of the dose (sequential vs. concurrent). Methods This open-label, phase II randomized controlled trial enrolled 70 resectable locally advanced ESCC patients from July 2019 to September 2020 (Phase I) and February 2022 to June 2023 (Phase II), Patients were randomized 1:1 to the sequential group (paclitaxel/cisplatin on day 1, toripalimab on day 3) or the concurrent group (all drugs on day 1). The primary endpoint was the pathological complete remission (pCR), secondary endpoints included major pathologic response (MPR), safety, and 5-year survival (OS/DFS). Results Among 54 surgical patients, Overall pCR was 22.2% (12/54), With no significant difference between the sequential group and the control group (17.8% vs. 26.9%, p = 0.636). Imaging showed an objective response rate (ORR) of 57.1% (40/70), with comparable OS (p = 0.797) and DFS (p = 0.715) between groups. In terms of safety, Grade 3–5 treatment-related adverse events (TRAEs) occurred in 14.2% (10/70), and the incidence of nausea/vomiting and diarrhea was greater in the control group (p < 0.05). There were 6 treatment-related deaths (The control group:5 vs. The sequential group:1). Conclusion There was no significant difference in pCR or survival outcomes between sequential and concurrent immunochemotherapy, but the concurrent strategy led to an increased risk of nausea/vomiting, diarrhea, and fatal immune-related adverse events (irAEs).
Reference Key
openalex_W7203897103 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yan Zheng, Jiwei Wu, Lingdi Zhao, Guanghui Liang, Yi Qin, Keting Li, Quanli Gao, Wenqun Xing
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.231
URL
https://doi.org/10.1093/dote/doag077.231
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.